Yosef Yarden

Q: What Schools Are Affiliated With Yosef Yarden

Yosef Yarden is affiliated with the following schools: Yale University, Weizmann Institute of Science, Tel Aviv University, Stanford University, New York University

Yosef Yarden's AcademicInfluence.com Rankings

Yosef Yarden

Biology

#3200

World Rank

#4928

Historical Rank

Molecular Biology

#213

World Rank

#217

Historical Rank

biology Degrees

Download Badge

Biology

Yosef Yarden's Degrees

PhD Molecular Biology Tel Aviv University
Bachelors Life Sciences Tel Aviv University

Why Is Yosef Yarden Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Yosef Yarden's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Untangling the ErbB signalling network (2001) (6547)
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells (1984) (2426)
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences (1984) (2385)
EGF–ERBB signalling: towards the systems level (2006) (1941)
Growth factor receptor tyrosine kinases. (1988) (1648)
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. (2001) (1623)
Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. (1987) (1557)
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor (1996) (1071)
Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. (1999) (1027)
Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors (1986) (1004)
c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. (1998) (902)
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. (1996) (817)
The ERBB network: at last, cancer therapy meets systems biology (2012) (747)
The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions (1997) (744)
Derailed endocytosis: an emerging feature of cancer (2008) (700)
ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. (1996) (697)
Biology of HER2 and Its Importance in Breast Cancer (2001) (679)
Feedback regulation of EGFR signalling: decision making by early and delayed loops (2011) (608)
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer (2000) (603)
The deaf and the dumb: the biology of ErbB-2 and ErbB-3. (2003) (595)
Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit (1992) (585)
Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. (2000) (565)
Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. (1987) (550)
Isolation of the Neu HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells (1992) (515)
Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis (1997) (493)
Expression of epidermal growth factor receptors in human brain tumors. (1984) (491)
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. (1999) (490)
A module of negative feedback regulators defines growth factor signaling (2007) (486)
ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation (2015) (478)
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers (2020) (475)
Neu differentiation factor is a neuron-glia signal and regulates survival, proliferation, and maturation of rat schwann cell precursors (1995) (451)
Regulation of MAPKs by growth factors and receptor tyrosine kinases. (2007) (445)
Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers (1998) (443)
Roles for growth factors in cancer progression. (2010) (438)
Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. (1987) (435)
Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases (2004) (421)
The EGF receptor family: spearheading a merger of signaling and therapeutics. (2007) (417)
Developmental expression of two murine fibroblast growth factor receptors, flg and bek. (1991) (410)
The basic biology of HER2. (2001) (404)
Signal transduction and oncogenesis by ErbB/HER receptors. (2004) (396)
Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor (2015) (381)
Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53 (2001) (370)
Sensitivity of Mature ErbB2 to Geldanamycin Is Conferred by Its Kinase Domain and Is Mediated by the Chaperone Protein Hsp90* (2001) (368)
Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway (2000) (366)
Developmental expression of c-kit, a proto-oncogene encoded by the W locus. (1990) (366)
Endocytosis of Receptor Tyrosine Kinases Is Driven by Monoubiquitylation, Not Polyubiquitylation* (2003) (354)
Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases (2001) (343)
Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. (2000) (337)
The RING Finger of c-Cbl Mediates Desensitization of the Epidermal Growth Factor Receptor* (1999) (322)
Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase (1999) (316)
LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation (2004) (315)
Neu and its ligands: From an oncogene to neural factors (1993) (308)
A mutant EGF‐receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling (2002) (272)
Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies. (1983) (270)
The circRNA–microRNA code: emerging implications for cancer diagnosis and treatment (2019) (261)
Drug‐induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy (2002) (241)
Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. (1990) (241)
B61 is a ligand for the ECK receptor protein-tyrosine kinase (1994) (238)
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. (2005) (231)
Bivalence of EGF‐like ligands drives the ErbB signaling network (1997) (230)
Cell‐type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER‐2 suggests complex ligand‐receptor relationships. (1993) (228)
Alternative Intracellular Routing of ErbB Receptors May Determine Signaling Potency* (1998) (228)
Hsp90 Recognizes a Common Surface on Client Kinases* (2006) (227)
A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization (1991) (219)
Regulation of cell proliferation by epidermal growth factor. (1983) (218)
The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. (1998) (215)
Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. (1991) (214)
A single autophosphorylation site confers oncogenicity to the Neu/ErbB‐2 receptor and enables coupling to the MAP kinase pathway. (1994) (213)
A reciprocal tensin-3–cten switch mediates EGF-driven mammary cell migration (2007) (206)
The avian beta-adrenergic receptor: primary structure and membrane topology. (1986) (203)
Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2 (1995) (196)
Endocytosis and cancer. (2013) (195)
p38 MAP kinase mediates stress‐induced internalization of EGFR: implications for cancer chemotherapy (2006) (195)
A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors (1997) (194)
Molecular analysis of signal transduction by growth factors. (1988) (193)
Sprouty Fine-Tunes EGF Signaling through Interlinked Positive and Negative Feedback Loops (2003) (191)
Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. (1993) (186)
Threonine Phosphorylation Diverts Internalized Epidermal Growth Factor Receptors from a Degradative Pathway to the Recycling Endosome* (2000) (184)
Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. (1996) (183)
The Achilles Heel of ErbB-2/HER2: Regulation by the Hsp90 Chaperone Machine and Potential for Pharmacological Intervention (2004) (176)
Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. (1996) (171)
Epidermal growth factor induces electrically silent Na+ influx in human fibroblasts. (1982) (170)
Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. (1995) (169)
SnapShot: EGFR Signaling Pathway (2007) (166)
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis (2009) (166)
c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. (1992) (163)
Epiregulin Is a Potent Pan-ErbB Ligand That Preferentially Activates Heterodimeric Receptor Complexes* (1998) (162)
The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction (1995) (160)
Suppressors of Cytokine Signaling 4 and 5 Regulate Epidermal Growth Factor Receptor Signaling* (2005) (160)
Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy (2010) (160)
Cbl-b-dependent Coordinated Degradation of the Epidermal Growth Factor Receptor Signaling Complex* (2001) (159)
Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor. (1981) (158)
Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy (2007) (156)
A confined variable region confers ligand specificity on fibroblast growth factor receptors: implications for the origin of the immunoglobulin fold. (1992) (156)
Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. (2004) (153)
Conjugation to Nedd8 Instigates Ubiquitylation and Down-regulation of Activated Receptor Tyrosine Kinases* (2006) (153)
Ligand‐Independent Degradation of Epidermal Growth Factor Receptor Involves Receptor Ubiquitylation and Hgs, an Adaptor Whose Ubiquitin‐Interacting Motif Targets Ubiquitylation by Nedd4 (2002) (152)
An Immunological Approach Reveals Biological Differences between the Two NDF/Heregulin Receptors, ErbB-3 and ErbB-4 (*) (1996) (151)
Src promotes destruction of c-Cbl: Implications for oncogenic synergy between Src and growth factor receptors (2003) (149)
Neu Differentiation Factor/Neuregulin Isoforms Activate Distinct Receptor Combinations* (1996) (149)
Oncogenic growth factor receptors: implications for signal transduction therapy. (2004) (148)
Brain neurons and glial cells express Neu differentiation factor/heregulin: a survival factor for astrocytes. (1994) (148)
ErbB Tyrosine Kinases and the Two Neuregulin Families Constitute a Ligand-Receptor Network (1998) (146)
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling (2007) (143)
Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor. (1992) (142)
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling (2010) (139)
A specific combination of substrates is involved in signal transduction by the kit‐encoded receptor. (1991) (137)
Granulocyte-Macrophage Colony-stimulating Factor Stimulates JAK2 Signaling Pathway and Rapidly Activates p93, STAT1 p91, and STAT3 p92 in Polymorphonuclear Leukocytes (*) (1996) (136)
Hsp90 restrains ErbB‐2/HER2 signalling by limiting heterodimer formation (2004) (134)
Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation (1997) (132)
CircRNAs: role in human diseases and potential use as biomarkers (2021) (131)
Rotational diffusion of epidermal growth factor complexed to cell surface receptors reflects rapid microaggregation and endocytosis of occupied receptors. (1981) (131)
Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase. (1992) (124)
Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21. (1993) (123)
Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network (1998) (121)
Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells (2007) (118)
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth (2013) (117)
Coupled pre-mRNA and mRNA dynamics unveil operational strategies underlying transcriptional responses to stimuli (2011) (116)
Convergence of signaling by interleukin-3, granulocyte-macrophage colony-stimulating factor, and mast cell growth factor on JAK2 tyrosine kinase. (1994) (116)
Insulin and insulinomimetic agents induce activation of phosphatidylinositol 3'-kinase upon its association with pp185 (IRS-1) in intact rat livers. (1992) (116)
An Unbiased Screen Identifies DEP-1 Tumor Suppressor as a Phosphatase Controlling EGFR Endocytosis (2009) (113)
Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. (1991) (112)
The C‐terminus of the kinase‐defective neuregulin receptor ErbB‐3 confers mitogenic superiority and dictates endocytic routing (1999) (112)
EGF Decreases the Abundance of MicroRNAs That Restrain Oncogenic Transcription Factors (2010) (112)
KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. (1993) (112)
Steel factor and c-kit protooncogene: genetic lessons in signal transduction. (1994) (110)
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR (2013) (109)
Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. (1992) (108)
The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin (1998) (106)
Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. (2011) (104)
Activity-dependent regulation of Neu differentiation factor/neuregulin expression in rat brain. (1998) (102)
Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation (2005) (100)
Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells. (1995) (100)
Epigen, the Last Ligand of ErbB Receptors, Reveals Intricate Relationships between Affinity and Mitogenicity* (2005) (99)
Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior. (1994) (97)
Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. (1990) (97)
Systems Biology of Growth Factor‐Induced Receptor Endocytosis (2009) (97)
Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene. (1989) (97)
Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. (1996) (95)
EGR1 and the ERK‐ERF axis drive mammary cell migration in response to EGF (2012) (94)
The murine flg gene encodes a receptor for fibroblast growth factor. (1990) (94)
Neu Differentiation Factor Stimulates Phosphorylation and Activation of the Sp1 Transcription Factor (1999) (94)
Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression (2011) (92)
Epiregulin is Up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. (2000) (92)
STAT Protein Recruitment and Activation in c-Kit Deletion Mutants* (1999) (91)
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. (2006) (90)
The role of ubiquitylation in signaling by growth factors: implications to cancer. (2003) (88)
Tumor Cell Invasion Can Be Blocked by Modulators of Collagen Fibril Alignment That Control Assembly of the Extracellular Matrix. (2016) (86)
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 (2016) (86)
Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation. (1992) (86)
Interspecies molecular chimeras of kit help define the binding site of the stem cell factor (1993) (85)
ErbB Receptors and EGF-like Ligands: Cell Lineage Determination and Oncogenesis Through Combinatorial Signaling (1997) (84)
ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture. (2002) (83)
miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours (2012) (83)
EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer (2015) (81)
Purification of an active EGF receptor kinase with monoclonal antireceptor antibodies. (1985) (80)
c-Cbl Is a Suppressor of the Neu Oncogene* (2000) (78)
Molecular approach to breast cancer treatment. (2004) (77)
Roles for a Cytoplasmic Tyrosine and Tyrosine Kinase Activity in the Interactions of Neu Receptors with Coated Pits (*) (1995) (73)
Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains (2007) (73)
LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer (2016) (73)
Polar expression of ErbB-2/HER2 in epithelia. Bimodal regulation by Lin-7. (2003) (70)
Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features (2018) (70)
ErbB-3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytes. (1995) (70)
Biochemical analysis of the ligand for the neu oncogenic receptor. (1991) (70)
The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors (2015) (69)
Hsp90 increases LIM kinase activity by promoting its homo‐dimerization (2006) (68)
Pigmentation and Proliferation of Human Melanocytes and the Effects of Melanocyte‐Stimulating Hormone and Ultraviolet B Light a (1993) (68)
Tumor suppressor microRNAs: A novel non‐coding alliance against cancer (2014) (67)
Neu Differentiation Factors: A Family of Alternatively Spliced Neuronal and Mesenchymal Factors (1994) (65)
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance (2021) (64)
Soluble c-kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor. (1993) (63)
Epigenetic silencing of miR-145-5p contributes to brain metastasis (2015) (63)
Regulation of signalling by microRNAs. (2012) (63)
Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. (1996) (63)
ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti‐cancer therapy (2006) (62)
Expression of amphiregulin, cripto-1, and heregulin-alpha in human breast-cancer cells. (1993) (62)
EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism (2010) (61)
Cytoplasmic control of cell adhesion. (1992) (61)
Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer (2015) (61)
c-Cbl is a critical modulator of the Ron tyrosine kinase receptor (2003) (61)
Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment (2014) (60)
HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors (2007) (60)
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy (2020) (59)
AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer (2019) (59)
Neu Differentiation Factor Inhibits EGF Binding (1995) (57)
A recombinant ectodomain of the receptor for the stem cell factor (SCF) retains ligand-induced receptor dimerization and antagonizes SCF-stimulated cellular responses. (1992) (56)
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18 (2016) (55)
Cancer therapeutic antibodies come of age: Targeting minimal residual disease (2007) (55)
Kinase-mediated quasi-dimers of EGFR. (2010) (55)
PCR-based identification of new receptors: molecular cloning of a receptor for fibroblast growth factors. (1991) (53)
A nonmitogenic analogue of epidermal growth factor induces early responses mediated by epidermal growth factor (1982) (53)
The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity (2016) (52)
The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility (2014) (52)
Signal transduction: Molecular ticket to enter cells (2002) (51)
Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling (2011) (50)
Structural organization of the murine c-kit proto-oncogene. (1992) (49)
Flg-2, a new member of the family of fibroblast growth factor receptors. (1991) (48)
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3 (2016) (47)
A non-mitogenic analogue of epidermal growth factor enhances the phosphorylation of endogenous membrane proteins. (1981) (47)
The key roles of cancer stem cell-derived extracellular vesicles (2021) (46)
The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms (2000) (46)
Phosphorylation of Carboxyl-terminal Tyrosines Modulates the Specificity of Sprouty-2 Inhibition of Different Signaling Pathways* (2005) (45)
Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface (2018) (44)
Consistency test of the cell cycle: roles for p53 and EGR1. (2012) (43)
Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. (2012) (43)
Context-specific microRNA analysis: identification of functional microRNAs and their mRNA targets (2012) (43)
Monoubiquitylation: a recurrent theme in membrane protein transport. (2006) (43)
Examination of HER3 targeting in cancer using monoclonal antibodies (2015) (43)
Csk Homologous Kinase, a Novel Signaling Molecule, Directly Associates with the Activated ErbB-2 Receptor in Breast Cancer Cells and Inhibits Their Proliferation* (1998) (43)
Microaggregation of hormone‐occupied epidermal growth factor receptors on plasma membrane preparations. (1986) (43)
Molecular requirements for the effect of neuregulin on cell spreading, motility and colony organization (2000) (42)
Genomic amplicons target vesicle recycling in breast cancer. (2009) (42)
Structure‐function analyses of the kit receptor for the steel factor (1993) (42)
The basic biology of HER 2 (2005) (40)
Studies on the Structure and Function of Glycosylated and Nonglycosylated neu Differentiation Factors (1995) (40)
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors (2017) (40)
RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer (2017) (39)
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2 (2013) (38)
Monoclonal antibody reactive with the human epidermal-growth-factor receptor recognizes the blood-group-A antigen (1983) (38)
An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity. (1992) (38)
Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions (2012) (37)
A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways (2018) (36)
Morphogenetic effects of neuregulin (neu differentiation factor) in cultured epithelial cells. (1998) (36)
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors (2016) (36)
SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors (2018) (35)
Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer (2015) (35)
A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis (2011) (34)
An antibody to amphiregulin, an abundant growth factor in patients’ fluids, inhibits ovarian tumors (2016) (34)
Receptor Tyrosine Kinases: Family and Subfamilies (2015) (34)
Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. (2016) (34)
Primary amines do not prevent the endocytosis of epidermal growth factor into 3T3 fibroblasts. (1981) (34)
Geldanamycins Trigger a Novel Ron Degradative Pathway, Hampering Oncogenic Signaling* (2006) (33)
Receptor tyrosine kinase expression in astrocytic lesions: similar features in gliosis and glioma. (1993) (32)
Roles for Growth Factors in Cancer (2010) (32)
Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression (2015) (32)
Monoubiquitinylation regulates endosomal localization of Lst2, a negative regulator of EGF receptor signaling. (2009) (31)
The deaf and the dumb (2003) (29)
Beta-Catenin/HuR Post-Transcriptional Machinery Governs Cancer Stem Cell Features in Response to Hypoxia (2013) (29)
Medullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behavior. (1994) (29)
Expression of erbB receptors and their ligands in breast cancer: implications to biological behavior and therapeutic response. (2000) (28)
Differences between phosphotyrosine accumulation and Neu/ErbB‐2 receptor expression in astrocytic proliferative processes: Implications for glial oncogenesis (1996) (28)
Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance. (2011) (28)
MiRNA-513a-5p inhibits progesterone receptor expression and constitutes a risk factor for breast cancer: the hOrmone and Diet in the ETiology of breast cancer prospective study (2018) (27)
Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase. (1994) (27)
Monoclonal antibodies against epidermal growth factor receptor induce prolactin synthesis in cultured rat pituitary cells (GH3). (1983) (26)
Structure and function of epigen, the last EGFR ligand. (2014) (26)
Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. (2020) (25)
Enhanced expression of heregulin in c‐erb B‐2 and c‐Ha‐ras transformed mouse and human mammary epithelial cells (1996) (25)
TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment (2021) (25)
Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies (2000) (25)
Downregulating oncogenic receptor: From bench to clinic (2016) (24)
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor (2020) (24)
Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands (2010) (24)
MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer. (2016) (24)
Receptor functions and ligand-dependent transforming potential of a chimeric kit proto-oncogene (1990) (24)
The EGF receptor kinase: evidence for allosteric activation and intramolecular self-phosphorylation. (2008) (24)
Advances in Brief Tumor-inhibitory Antibodies to HER-2 / ErbB2 May Act by Recruiting c-Cbl and Enhancing Ubiquitination of HER-21 (2000) (23)
Downregulation of microRNAs 145-3p and 145-5p Is a Long-term Predictor of Postmenopausal Breast Cancer Risk: The ORDET Prospective Study (2014) (23)
Cancer Immunotherapy: The Dawn of Antibody Cocktails. (2018) (23)
Bortezomib‐induced pro‐inflammatory macrophages as a potential factor limiting anti‐tumour efficacy (2016) (23)
Pancreatic cancer ascites xenograft–an expeditious model mirroring advanced therapeutic resistant disease (2017) (22)
Notch inhibition overcomes resistance to Tyrosine Kinase Inhibitors in EGFR-driven lung adenocarcinoma. (2019) (22)
MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression (2015) (21)
Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease (2015) (21)
Protein kinase C-dependent release of a functional whole extracellular domain of the mast cell growth factor (MGF) receptor by MGF-dependent human myeloid cells. (1994) (21)
Basic cancer research is essential for the success of personalised medicine. (2013) (21)
The rebirth of a phoenix: ovarian cancers are addicted to ErbB-3. (2010) (21)
The locus of microRNA-10b (2013) (21)
A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy (2018) (21)
Signal transduction by the neu/ebrB-2 receptor: A potential target for anti-tumor therapy (1992) (20)
A cromoglycate binding protein from rat mast cells of a leukemia line is a nucleoside diphosphate kinase. (1992) (20)
Proteomic patterns associated with response to breast cancer neoadjuvant treatment (2020) (19)
Protein kinases in cellular signal transduction: tyrosine kinase growth factor receptors and protein kinase C. (1986) (19)
ErbB‐4 may control behavior of prostate cancer cells and serve as a target for molecular therapy (2007) (18)
Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth (2011) (18)
ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. (2015) (18)
The short and the long: non-coding RNAs and growth factors in cancer progression. (2017) (18)
Oncogenic forms of the neu / HER 2 tyrosine kinase are permanently coupled to phospholipase Cy (18)
Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone (2017) (17)
Enlightened receptor dynamics (2004) (17)
Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings (2015) (17)
Targeting oncogenic receptor : From molecular physiology to currently the standard of target therapy (2017) (16)
Epidermal Growth-Factor – Induced Transcript Isoform Variation Drives Mammary Cell Migration (2013) (16)
Irreversible modifications of receptor tyrosine kinases (2018) (16)
Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library. (2000) (15)
The epidermal growth factor receptor as a substrate for a kinase-splitting membranal proteinase. (1988) (15)
PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR (2021) (15)
Coordinated Pulses of mRNA and of Protein Translation or Degradation Produce EGF-Induced Protein Bursts. (2017) (14)
ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma (2019) (14)
Database-independent Protein Sequencing (DiPS) Enables Full-length de Novo Protein and Antibody Sequence Determination * (2017) (14)
Targeting ErbB‐1 and ErbB‐4 in irradiated head and neck cancer: Results of in vitro and in vivo studies (2013) (13)
Antibodies to two defined regions of the transforming protein pp60src interact specifically with the epidermal growth factor receptor kinase system. (1984) (13)
Biochemistry of HER2 oncogenesis in breast cancer. (2000) (13)
ERK-ERF-EGR1, a novel switch underlying acquisition of a motile phenotype (2013) (12)
Activation of a transfected FGFR‐1 receptor in Madin‐Darby epithelial cells results in a reversible loss of epithelial properties (1995) (12)
p91 STAT1 activation in interleukin-3-stimulated primary acute myeloid leukemia cells. (1996) (12)
Structural Aspects of Receptor Dimerization (1995) (12)
Receptor tyrosine kinases: the emerging tip of systems control. (2008) (11)
Receptor Tyrosine Kinase Expression in Astrocytic Lesions (1993) (11)
Transmembrane signalling receptors for cytokines and growth factors (1991) (11)
MAP Kinase activation by receptor tyrosine kinases: in control of cell migration. (2010) (10)
Monoclonal Antibodies against the Membrane Receptor for Epidermal Growth Factor: A Versatile Tool for Structural and Mechanistic Studies (1984) (10)
Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation (2020) (10)
The biological framework: translational research from bench to clinic. (2010) (10)
Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies. (2011) (9)
qCMA: a desktop application for quantitative collective cell migration analysis. (2013) (9)
CRISPR‐assisted receptor deletion reveals distinct roles for ERBB2 and ERBB3 in skin keratinocytes (2017) (9)
The Epidermal Growth Factor Receptor Family (2010) (8)
ErbB Tyrosine Kinases and the Two Neuregulin Families Constitute a Ligand-Receptor Network (1998) (8)
Interfering with the Dimerization of the ErbB Receptors by Transmembrane Domain-Derived Peptides Inhibits Tumorigenic Growth in Vitro and in Vivo. (2016) (8)
Polypeptide-Hormone-Induced Receptor Clustering and Internalization (1983) (8)
A Crossroad of microRNAs and Immediate Early Genes (IEGs) Encoding Oncogenic Transcription Factors in Breast Cancer (2012) (8)
Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models (2021) (8)
Multimerization of ERBB2/HER2 specific aptamer leads to improved receptor binding. (2015) (8)
Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy. (2015) (8)
Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients (2021) (8)
ErbB 4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy (2006) (8)
Receptor-like oncogenes: functional analysis through novel experimental approaches. (1990) (8)
EGF receptor family: twisting targets for improved cancer therapies (2014) (8)
Steering tumor progression through the transcriptional response to growth factors and stroma (2014) (8)
The EGFR/ERBB Receptor Family (2015) (7)
Structural aspects of receptor dimerization. c-kit as an example. (1995) (7)
The heregulin gene can be included in the 8p12 amplification unit in human breast cancer (1994) (7)
The era of ErbB-receptor-targeted therapies: advances toward personalized medicine. (2005) (6)
Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53 (2021) (6)
Antibody-Mediated Receptor Endocytosis: Harnessing the Cellular Machinery to Combat Cancer (2013) (5)
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer (2022) (5)
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans (2022) (5)
Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer (2020) (5)
THE ERBB FAMILY OF RECEPTOR TYROSINE KINASES (2003) (5)
Vesicle Trafficking in Cancer (2013) (5)
TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis (2021) (4)
CHAPTER 71 – EGF Receptor Family (2003) (4)
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. (2014) (4)
The prospects of tumor chemosensitivity testing at the single-cell level. (2020) (4)
Neuregulins and Their Receptors: Meeting Report A Versatile Signaling Module in Organogenesis and Oncogenesis (1997) (4)
Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors. (2022) (3)
Cancer Immunotherapy: More Is (Much) Better (2015) (3)
Differences in response of breast cancer molecular profiles of patients likely to respond to either tyrosine kinase inhibitors or to erbB targeted therapies. (2004) (3)
Basic cancer research: why it is essential for the future of cancer therapy. (2014) (3)
Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways (2018) (3)
Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr701 phosphorylation (2020) (3)
The biological framework: translational research from bench to clinic. (2010) (3)
Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies. (2019) (3)
Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins (2022) (3)
In vitro and in vivo assays of monoubiquitination of receptor tyrosine kinases. (2006) (2)
The International Consortium on Systems Biology of Receptor Tyrosine Kinase Regulatory Networks. (2005) (2)
ErbB Tyrosine Kinases and the Two Neuregulin Families Constitute a Ligand-Receptor Network (1999) (2)
Functional Cell Biology: An Overview (2016) (2)
Signaling by growth factor receptors. (2004) (2)
Roles for growth factors and mutations in metastatic dissemination (2021) (2)
Methyl-CpG binding domain 2 (Mbd2) is an Epigenetic Regulator of Autism-Risk Genes and Cognition (2020) (2)
Phosphoamino acid specificity of the EGF-receptor kinase system in normal mitogenically responsive human cells (1983) (2)
Cadherin endocytosis (2009) (2)
Methyl-CpG binding domain 2 (Mbd2) deficiency causes cognitive, social and emotional functional deficits (2018) (2)
The EGFR/ErbB Family in Breast Cancer: From Signalling to Therapy (2011) (2)
Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits (2021) (2)
Oncogenic Receptor Tyrosine Kinases (2003) (2)
Computational and Modeling Aspects of RTK Networks (2015) (2)
Abstract 991: OVO-like genes are master regulators of the epithelial fate in breast cancer (2022) (1)
Receptor Functions andLigand-Dependent Transforming Potential ofa Chimeric kitProto-Oncogene (1990) (1)
Growth factors and ErbB/HER tyrosine kinases: How do they contribute to malignancy? (1997) (1)
Present and future breast cancer management-bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. (2014) (1)
[Basic principles of signal transduction]. (2005) (1)
Structural and Functional Analysis of Cell Surface Receptors with Tyrosine Kinase Activity (1986) (1)
Nucleoporin-93 overexpression overcomes multiple nucleocytoplsamic trafficking bottlenecks to permit robust metastasis (2020) (1)
Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors (2021) (1)
Molecular steps in the action and regulation of epidermal growth factor: a cellular mitogen. (1982) (1)
Feedback regulation of biological networks: Examples relevant to signalling pathways and resistance to pharmacological interceptors. (2016) (1)
Erratum: Insulin and insulinomimetic agents induce activation of phosphatidylinositol 3'-kinase upon its association with pp 185 (IRS-1) in intact rat livers (Journal of Biological Chemistry (1992) 267 (17483-17486)) (1993) (1)
Growth factors and associated signalling pathways in tumour progression and in cancer treatment (2019) (1)
5’isomiR-183-5p|+2 elicits tumor suppressor activity in a negative feedback loop with E2F1 (2022) (1)
EpCAM, a novel oncogenic receptor and its target therapy (2018) (1)
Endocytosis of Receptor Tyrosine Kinases: Implications for Signal Transduction by Growth Factors (2013) (1)
Table of Contents (1996) (0)
Overview of HER2 and Type I growth factor receptor influences in breast cancer development and biology (2002) (0)
On the notion of synergy of monoclonal antibodies as drugs (2009) (0)
Recycling of HER-ErbB Receptors: Rescue From Apoptosis and Targets for Immunotherapy (2002) (0)
A mutant EGF‐receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling (0)
P2-03-04: Novel Pathways Underlying the Initiation and Transition of DCIS to IDC of HER2−Overexpressing Breast Cancer Model. (2011) (0)
HER2/neu oncoprotein of human adenocarcinomas: an amplifier of signal transduction by stromal growth factor (1999) (0)
Structural and Functional Aspects of Signal Transduction by Receptor Tyrosine Kinases (1989) (0)
Methods and compositions for cancer therapy and for the predictability of reactions to this treatment (1992) (0)
Functional cell biology (2016) (0)
HER2-Associated Breast Cancer Signature Using a 3D Culture Model. (2009) (0)
Brain Tumors Expression of Epidermal Growth Factor Receptors in Human Updated Version (2006) (0)
ErbB-4 MayControlBehaviorofProstateCancerCells and Serve as aTarget forMolecularTherapy (2007) (0)
Abstract BL-1: Brinker Award Lecture: How Does HER2 Contribute to Breast Cancer Progression? (2012) (0)
Edinburgh Research Explorer AhR controls redox homeostasis and shapes the tumour microenvironment in BRCA1-associated breast cancer (2019) (0)
Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies (2022) (0)
Growth Factors (2021) (0)
Cell activation: Genetic approaches. Advances in regulation of cell growth. Vol. 2: Edited by J.J. Mond, J.C. Cambier and A. Weiss. Raven Press, New York, 1991. 334 pp. $131.50 (1992) (0)
Immune clustering reveals molecularly distinct subtypes of lung adenocarcinoma (2023) (0)
Author Correction: Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr701 phosphorylation (2021) (0)
Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis (2022) (0)
Toward Understanding the Glucocorticoid Receptor Network in Cancer (2017) (0)
ErB-2/HER2 Oncogene in Breast Cancer: Does Bivalency of Growth Factors Drive Tumorigenicity Through Receptor Heterodimerization (1998) (0)
EGF-family ligands betacellulin and neuregulin-4 direct the differentiation of developing mouse islet cells (2000) (0)
Abstract SY23-02: RTK endocytosis and other feedback mechanisms in cancer (2011) (0)
Systemic approaches to oncogenic networks and to pharmaceutical perturbations (2009) (0)
Kinase‐mediated quasi‐dimers of EGFR (2010) (0)
Methods and compositions for cancer treatment and prognosis of reactions to those indicated treatments. (1992) (0)
Nucleoporin-93 Overcomes Multiple Nucleocytoplasmic Trafficking Bottlenecks and Permits Robust Metastasis (2021) (0)
Abstract A52: Extracellular matrix regulation of ErbB3 in a subset of wild-type BRAF/NRAS melanoma (2015) (0)
165 INVITED Systems approach to growth factor signaling and to therapeutic intervention (2007) (0)
Table 1, Proteins involved in endocytosis of RTKs (2013) (0)
323 Targeted use of combination of erbB targeted therapy (2004) (0)
Rational Development of Targeted Cancer Therapies Using Biomarkers (2006) (0)
Regulate Epidermal Growth Factor Suppressors of Cytokine Signaling 4 and 5 Mechanisms of Signal Transduction : (2005) (0)
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer (2014) (0)
ACK1 is dispensable for development, skin tumor formation, and breast cancer cell proliferation (2021) (0)
The promise offered by merging systems, biology and targeted therapy of cancer (2012) (0)
Negative regulation of RTKs: receptor ubiquitylation, endocytosis and feedback loops (2007) (0)
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy (2020) (0)
10 The HER2 and EGFR alliance in cancer: defects in system control (2010) (0)
Corrigendum to “Basic cancer research is essential for the success of personalised medicine” [European Journal of Cancer 49(12) pp. 2619–2620 (2013)] (2013) (0)
MA07.05 Phase 1b/2 Study of Combined HER Inhibition in Refractory EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (2022) (0)
The Membrane Receptor for Epidermal Growth Factor (1985) (0)
Activity-dependent regulation of Neu differentiation factoryneuregulin expression in rat brain (central nervous systemyneural plasticityytyrosine kinase) (1998) (0)
36 Network and Systems Biology in Cancer (2012) (0)
Breast disease. Introduction. (2000) (0)
Abstract A84: Synaptojanin-2 and microRNA-31 control invadopodia and metastasis by regulating vesicular trafficking (2013) (0)
PD-L1 Recruits Phospholipase C and Enhances EGFR Signaling: Relevance to Resistance of EGFR-Mutated Lung Tumors to Immunotherapy (2020) (0)
Methyl-CpG binding domain 2 (Mbd2) deficiency causes cognitive, social and emotional deficits and down-regulation of ortholog Autism risk genes (2018) (0)
The ERBB family of proteins (originally named because of their homology to the erythroblastoma viral gene product, v-erbB) comprises four receptors (ERBB1–4, also known as HER1–4) and 13 polypeptide extra cel- (2006) (0)
Monoclonal antibodies against epidermal growthfactor receptor induce prolactin synthesis incultured ratpituitary cells (GH3) (membrane receptor/gene expression/hormone (1983) (0)
White paper: The International Receptor Tyrosine Kinase Networks Consortium (2005) (0)
Abstract NT-121: AN ANTI-AMPHIREGULIN ANTIBODY AS POTENTIAL TREATMENT FOR OVARIAN CANCER (2019) (0)
The avian f 3-adrenergic receptor : Primary structure and membrane topology ( adenylate cyclase / cDNA / rhodopsin / G protein ) (0)
Resistance of Lung Cancer to Kinase Inhibitors Specific to EGFR or ALK (2018) (0)
Transcription-based chronobiology of receptor tyrosine kinases: Relevance to cancer progression (2015) (0)
P2.42: An Immunotherapy Approach to Overcoming Resistance to Second and Third Generation EGFR Inhibitors: Track: Immunotherapy. (2016) (0)
LAD 1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors (2018) (0)
Reliable energy-based antibody humanization and stabilization (2022) (0)
Abstract C44: Targeting neuregulin1-ErbB3 signaling in wild-type BRAF/NRAS melanoma. (2013) (0)
Di erential expression of NDF / neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal di erentiation (1997) (0)
A Systems Biology Approach to Molecular Diagnostics in the ErbB-3/HER2 System (2007) (0)
The EGF receptor signalling system (2008) (0)
Abstract 3475: Diurnal suppression of EGFR signaling by glucocorticoids: implications for tumor progression and treatment (2015) (0)
Definition of resistance mechanisms (2007) (0)
Abstract A58: Antibodies to amphiregulin, an abundant growth factor in patients' fluids, inhibits tumor growth (2015) (0)
Growth and Differentiation of HCII Mammary Epithelial Cells (1995) (0)
Neural expression and chromosomal mapping of Neu differentiation factor to 8 pl 2p 21 ( polypeptide growth factor / receptor tyouine kinase / erbB2 / nervous system ) (2005) (0)
40: Proffered Paper: miRNA induces escape from NK cell-mediated cytotoxicity and resistance towards apoptosis in breast cancer (2014) (0)
Neu differentiation factor (NDF/heregulin) induces expression of adhesion molecules, increased cellular invasiveness, and is expressed in Paget's disease of the breast together with its receptors (1998) (0)
49 Molecular mechanisms of lung cancer development – how to use our knowledge of molecular biology in more effective therapies (2009) (0)
The Kit Receptor for the Stem Cell Factor: Genetic Lessons in Signal Transduction (1992) (0)
Author Correction: Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis (2023) (0)
Molecular Features Involved in Cell Surface Receptor Function and Their Role in Oncogenesis (1987) (0)
Monoclonal antibodies against epidermal growth factor receptor induce prolactin synthesis in cultured rat pituitary cells ( GH 3 ) ( membrane receptor / gene expression / hormone internalization ) (0)
Rationale for cetuximab in SCCHN (2006) (0)
Abstract 1097: First-line therapy based on kinase inhibitors and antibodies prevents resistance in EGFR-mutated lung cancer (2022) (0)
Abstract B069: The best is not enough—when it is alone: Current clinical doses of humanized anti-Her2 antibodies should be applied in combination to delay development of trastuzumab resistance by additively enhancing ADCC (2016) (0)
Long-termPredictorofPostmenopausalBreastCancerRisk: The ORDET Prospective Study (2014) (0)
Abstract 1165: Therapeutic targeting of glucocorticoid receptor in ETS rearranged cancer (2022) (0)
Growth factor signalling: ample opportunities for pharmaceutical interventions in oncology (2007) (0)
Regulation of receptor tyrosine kinases by ubiquitination (2002) (0)
5’isomiR-183-5p|+2 elicits tumor suppressor activity in a negative feedback loop with E2F1 (2022) (0)
Molecular Oncology: HER (2013) (0)
PROTOONCOGENES AND SIGNAL TRANSDUCTION PATHWAYS IN ASTROCVTES: DISTINGUISHING ASTROCYTOSIS FROM ASTROCYTOMA (1993) (0)
Engineered variants of the Ras effector protein RASSF5 (NORE1A) promote anticancer activities in lung adenocarcinoma (2021) (0)
CTEN and LKB1: Novel tumor biomarkers that give insight into resistance and response to tyrosine kinase inhibitor (TKI)-based therapies. (2007) (0)
Different map-kinase pathways involved in islet cell differentiation induced by betacellulin and neuregulin-4 (2001) (0)
The Use of Combination erbB Targeted Therapies (2004) (0)
Bortezomib-Induced Proinflammatory Macrophages Contribute to Multiple Myeloma Cell Aggressiveness (2015) (0)
S7 EGFR and HER2: Systemic approaches to oncogenic networks and to pharmaceutical perturbations (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Yosef Yarden?

Yosef Yarden is affiliated with the following schools: